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Background:  There  have  been  few reports  about  the clinical  signiﬁcance  of the  time  of  admission  for  acute
heart  failure  (AHF).
Methods: Five  hundred  thirty-one  patients  with  AHF  admitted  to  the  intensive  care  unit  (ICU)  were  ana-
lyzed. The  patients  were  assigned  to  either  the  daytime  HF  group  (n  = 195,  visited  from  08:00  to  20:00,
Group  D)  or  nighttime  HF group  (n = 336,  visited  from  20:00  to 08:00,  Group  N).  The  clinical  ﬁndings  and
outcomes  were  compared  between  these  groups.
Results:  The  systolic  blood  pressure  (SBP),  the  number  of  patients  with  clinical  scenario  (CS)  1,
and  the  heart  rate  (HR)  were  signiﬁcantly  higher  in  group  N (SBP,  171.0  ±  38.9 mmHg;  CS 1,
80.9%;  HR, 116.9  ±  28.0  beats/min)  than  in  group  D  (SBP,  154.2  ±  37.1 mmHg;  CS  1,  66.2%;  HR,
108.6  ±  31.4  beats/min).  The  patients  in  group  N were  more  likely  to  have  orthopnea  (91.1%)  than  those  inrognosis group D  (70.3%).  A  multivariate  logistic  regression  model  identiﬁed  a SBP  ≥164  mmHg  [odds  ratio  (OR):
2.043;  95%  conﬁdence  interval  (CI):  1.383–3.109],  HR  ≥114  beats/min  (OR:  1.490;  95%CI:  1.001–2.218),
and  orthopnea  (OR:  2.257;  95%CI:  1.377–3.701)  to be  independently  associated  with  Group  N.  The  length
of  ICU  stay  was shorter  in  group  N  (5.8  ±  10.5  days)  than  in group  D  (7.8  ±  11.5  days).
Conclusion:  The  nighttime  HF was  characterized  by high  SBP,  high  HR,  and  orthopnea,  and  the  length  of
ICU  stay  was  shorter  in  the  nighttime  HF  group.
2  Jap©  201
. Introduction
The European Society of Cardiology (ESC) guidelines proposed
he clinical classiﬁcation of acute heart failure (AHF) into ﬁve
ategories: peripheral edema/congestion; pulmonary edema;
ardiogenic shock (low output syndromes); high blood pressure
hypertensive heart failure (HF)]; and right HF [1].  Peripheral
dema/congestion and right HF might be classiﬁed as gradual
nset presentations, while pulmonary edema and high blood
ressure (hypertensive HF) might be classiﬁed as abrupt onset
resentations [2,3].
DOI of commentary article: http://dx.doi.org/10.1016/j.jjcc.2013.02.004.
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914-5087/$ – see front matter © 2012 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2012.10.004anese  College  of Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.
Although these differences in the HF categories might inﬂuence
the time of admission, there have so far been few reports examining
the differences in the clinical ﬁndings of AHF according to the time
of admission. It would be helpful for treating AHF to evaluate the
differences in the clinical ﬁndings according to the time of admis-
sion. In the present study, we  investigated the relationship between
the time of admission and the clinical ﬁndings on admission, the
management of HF, and the outcomes in patients with AHF.
2. Methods
2.1. Subjects
This study analyzed 531 patients with AHF who  were admitted
to the intensive care unit (ICU) of Chiba Hokusoh Hospital, Nippon
Medical School between January 2004 and October 2011. The data
were retrospectively reviewed from hospital medical records. AHF
was deﬁned as either new-onset HF or decompensation of chronic
vier Ltd. All rights reserved.
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F with symptoms sufﬁcient to warrant hospitalization [4]. HF was
iagnosed based on the Framingham criteria for a clinical diagnosis
f HF, based on the satisfaction of 2 major criteria or 1 major and
 minor criteria [2,5]. Patients with HF caused by acute coronary
yndrome were excluded from this study, and the AHF patients
ith in-hospital onset were also excluded from this study.
.2. Procedures
Patients were assigned to a daytime admission group (Group D),
hich included the patients admitted between 08:00 and 19:59,
nd a nighttime admission group (Group N), which included the
atients admitted between 20:00 and 07:59. The average bedtime
nd wake-up time of Japanese people over 50 years of age have
een reported to be around 22:00 and around 06:00, respectively.
he nighttime was thus deﬁned based on the average bedtime and
ake-up-time, including the sleeping hours.
The study examined the differences in the clinical informa-
ion on admission, treatments during the ﬁrst 5 days, and the
utcome between the two groups. The clinical ﬁndings included
he systolic blood pressure (SBP), heart rate (HR), body temper-
ture (BT), respiratory rate (RR), clinical scenarios (CS), presence
f orthopnea, laboratory data, chest X-ray results (pulmonary
ongestion and pleural effusion), and left ventricular ejection frac-
ion (LVEF) on echocardiograms between the two  groups. The
hite blood cell count (WBC), blood urea nitrogen (BUN), total
ilirubin, hemoglobin, brain natriuretic peptide (BNP), C-reactive
rotein (CRP), glucose, and arterial blood gas parameters (pH,
CO2, PO2, HCO3−, SaO2) were evaluated as laboratory ﬁndings.
he treatments included the use of respiratory supports and med-
cations prescribed during the ﬁrst 5 days. The duration of ICU
tay, hospital stay, and in-hospital mortality were evaluated as
utcomes.
The CS was deﬁned based on a previous report [6]; CS 1: dyspnea
nd/or congestion with SBP >140 mmHg; CS 2: dyspnea and/or con-
estion with SBP 100–140 mmHg; CS 3: dyspnea and/or congestion
ith SBP <100 mmHg. Pulmonary congestion on chest X-rays was
eﬁned based on the expansion of bilateral pulmonary arteries in
he hilar area or a butterﬂy shadow on the lung ﬁeld, and pleural
ffusion was deﬁned based on dulling of the cardiophrenic angle
n at least one side of the lungs or the existence of a vanishing
ig. 1. The distribution of acute heart failure patients according to the time of admission.
8:00  and 19:59), and 336 patients (63.3%) were admitted at night (between 20:00 and 0rdiology 61 (2013) 210–215 211
tumor. LVEF was calculated using the Teicholz method or Simpson’s
method on admission (Sonos 5500, Hewlett Packard, Palo Alto, CA,
USA or Vivid I, GE Yokogawa Medical, Tokyo, Japan).
The signiﬁcant factors associated with nighttime HF were deter-
mined by a multivariate logistic regression analysis. All variables
that were identiﬁed to be signiﬁcant by a univariate analysis on
admission were selected for further evaluation using the multivari-
ate logistic regression model. The arterial blood gas parameters (pH,
PCO2, PO2, HCO3−, SaO2) were signiﬁcantly correlated with each
other, therefore, the pH value was  selected for evaluation in the
multivariate logistic regression model. The continuous variables
were evaluated by dividing subjects into two  groups using a cut-
off value. The cut-off value of the continuous variables was decided
based on the median value.
2.3. Statistical analysis
All data were statistically analyzed using the StatView 5
software package (SAS Institute, Cary, NC, USA), and the SPSS
14.0J software program (SPSS Japan Institute, Tokyo, Japan). All
numerical data were expressed as the mean ± standard deviation.
An unpaired Student’s t-test or a one-way analysis of variance
(ANOVA) was used to compare mean values. Comparisons of all
proportions were performed with a chi-square analysis. The fac-
tors that were not normally distributed were compared by the
Mann–Whitney U test. A p-value of <0.05 was considered to
be statistically signiﬁcant. The signiﬁcant factors associated with
nighttime admission for HF were determined using the multivari-
ate logistic regression model.
2.4. Ethical concerns
The institutional review board at Chiba Hokusoh Hospital, Nip-
pon Medical School approved the study protocol.
3. Results3.1. Patient characteristics
The distribution of AHF patients according to the time of admis-
sion is shown in Fig. 1. Patients were admitted most frequently
 One hundred ninety-ﬁve patients (36.7%) were admitted during the day (between
7:59).
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Table 1
Differences in patient characteristics between the groups.
Daytime group
(n = 195)
Nighttime group
(n = 336)
p-Value
Age (years) 71.9 ± 11.7 72.3 ± 11.1 n.s.
Gender (male, %) 137 (70.3%) 221 (65.8%) n.s.
Etiology of heart failure
Ischemic heart disease 87 (44.6%) 142 (42.3%) n.s.
Cardiomyopathy 31 (15.9%) 53 (15.8%) n.s.
Hypertensive heart disease 39 (20.0%) 68 (20.2%) n.s.
Valvular disease 32 (16.4%) 69 (20.5%) n.s.
Other heart disease 6 (3.1%) 4 (1.2%) n.s.
Past medical history
Hypertension 145 (74.4%) 273 (81.3%) n.s.
Diabetes mellitus 81 (41.5%) 151 (44.9%) n.s.
Dyslipidemia 86 (44.1%) 164 (48.8%) n.s.
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Table 2
Comparison of the vital signs, clinical scenarios and orthopnea between the groups.
Daytime group
(n = 195)
Nighttime group
(n = 336)
p-Value
Vital signs
SBP (mmHg) 154.2 ± 37.1 171.0 ± 38.9 <0.001
HR  (beats/min) 108.6 ± 31.4 116.9 ± 28.0 <0.001
BT  (◦C) 36.3 ± 0.9 36.0 ± 1.0 0.002
RR  (time/min) 29.1 ± 7.7 32.0 ± 7.3 <0.001
Clinical scenarios
1 129 (66.2%) 272 (80.9%) <0.001
2 58 (29.7%) 55 (16.4%) <0.001
3 8  (4.1%) 9 (2.7%) n.s.
Orthopnea 137 (70.3%) 306 (91.1%) <0.001
SBP, systolic blood pressure; HR, heart rate; BT, body temperature; RR, respiratory
T
C
B
f-Values are for between-group comparisons.
round midnight, and less frequently around noon. One hun-
red ninety-ﬁve patients (36.7%) were admitted during the day
between 08:00 and 19:59), and 336 patients (63.3%) were admit-
ed during the night (between 20:00 and 07:59).
The relationship between the patient characteristics, includ-
ng baseline values on admission, and the time of admission is
hown in Table 1. The patient cohort was 66.5% male, with a mean
ge of 72.1 ± 11.3 years. Two hundred twenty-nine (43.1%) of the
atients had ischemic heart disease, and 302 (56.9%) patients had
on-ischemic heart diseases, including cardiomyopathy (n = 84),
ypertensive heart disease (n = 107), valvular disease (n = 101), and
ther heart diseases (n = 10). The etiology of HF was similar in each
roup. There were no statistically signiﬁcant differences in the age,
ender, etiology of HF, or past medical histories between the two
roups.
.2. Time of admission and clinical information on admission
The results of comparisons of the vital signs, the CS, and the
resence of orthopnea are shown in Table 2. The SBP was
igniﬁcantly higher in group N (170.1 ± 38.9 mmHg) than in
roup D (154.2 ± 37.1 mmHg); furthermore, the HR was also
igher in group N (116.9 ± 28.0 beats/min) than in group D
108.6 ± 31.4 beats/min). The number of cases of CS 1 was signif-
cantly higher in group N (80.9%) than in group D (66.2%), while the
able 3
omparison of the arterial blood gas, laboratory data, LVEF, and chest X-rays on admissio
Daytime group (n = 195) 
Arterial blood gas
pH 7.32 ± 0.14 
PCO2 (mmHg) 47.3 ± 20.9 
PO2 (mmHg) 108.1 ± 80.0 
HCO3− (mmol/L) 22.4 ± 4.5 
BE  (mmol/L) −2.8 ± 6.2 
SaO2 (%) 92.6 ± 8.0 
Lactate (mmol/L) 2.4 ± 2.0 
Laboratory data
WBC  (/L) 10,019 ± 3909 
BUN  (mg/dL) 30.0 ± 18.2 
Creatinine (mg/dL) 1.67 ± 1.48 
Hemoglobin (g/dL) 12.5 ± 2.7 
CRP  (mg/dL) 2.5 ± 4.4 
BS  (mg/dL) 190.8 ± 90.7 
BNP  (pg/mL) 1128.3 ± 1471.7 
LVEF  (%) 37.9 ± 17.4 
Chest  X-ray
Pleural effusion (yes, %) 153 (78.5%) 
Congestion (yes, %) 189 (96.9%) 
E, base excess; WBC, white blood cell; BUN, blood urea nitrogen;. BNP, brain natriureti
raction measured by echocardiogram. p-Values are for between-group comparisons.rate. p-Values are for between-group comparisons.
number of cases of CS 2 was signiﬁcantly lower in group N (16.4%)
than in group D (29.7%). The RR was  higher in group N (32.0 ± 7.3
times/min) than in group D (29.1 ± 7.7 times/min), and the BT was
lower in group N (36.0 ± 1.0 ◦C) than group D (36.3 ± 0.9 ◦C). The
patients in group N were more likely to have orthopnea (91.1%)
than those in group D (70.3%).
The results of the comparisons of the arterial blood gas param-
eters, laboratory data, LVEF, and chest X-rays are shown in Table 3.
The pH value on admission was signiﬁcantly lower in group N
(7.26 ± 0.14) than in group D (7.32 ± 0.14). The pCO2 values were
signiﬁcantly higher, and the HCO3− and the BE values were signif-
icantly lower, in group N than in group D. Some of the data were
not collected from all patients, but based on the patients who were
evaluated, the lactate levels were signiﬁcantly higher in group N
(3.2 ± 2.6 mmol/L) than in group D (2.4 ± 2.0 mmol/L).
The WBC  counts were signiﬁcantly higher in group N
(11,058 ± 4148/L)  than in group D (10,019 ± 3909/L), and the
serum levels of glucose were signiﬁcantly higher in group N
(230.6 ± 101.1 mg/dL) than in group D (190.8 ± 90.7 mg/dL). The
LVEF on admission showed no signiﬁcant difference between the
two groups.
Pleural effusions on chest X-ray were seen signiﬁcantly less
often in the patients in group N (70.5%) than in those in group D
(78.5%), while congestion on chest X-rays was  signiﬁcantly more
common in group N (96.9%) than in group D (99.7%).
n between the groups.
Nighttime group (n = 336) p-Value
7.26 ± 0.14 <0.001
52.5 ± 20.4 0.006
122.9 ± 100.6 n.s.
21.4 ± 4.0 0.009
−4.8 ± 5.4 <0.001
91.4 ± 9.5 n.s.
3.2 ± 2.6 0.004
11,058 ± 4148 0.005
26.8 ± 15.4 0.033
1.67 ± 1.84 n.s.
12.7 ± 2.8 n.s.
1.3 ± 2.4 <0.001
230.6 ± 101.1 <0.001
1118.0 ± 1067.0 n.s.
37.9 ± 16.4 n.s.
237 (70.5%) 0.046
335 (99.7%) 0.007
c peptide; CRP, C-reactive protein; BS, blood sugar; LVEF, left ventricular ejection
M.  Matsushita et al. / Journal of Ca
Table  4
Comparison of the medications prescribed during the ﬁrst 5 days after admission
and the respiratory support between the groups.
Daytime
group
(n = 195)
Nighttime
group
(n = 336)
p-Value
Respiratory support
Endotracheal intubation (yes, %) 46 (23.8%) 92 (27.3%) n.s.
NPPV (yes, %) 82 (42.1%) 166 (49.4%) n.s.
Medication
Furosemide (yes, %) 184 (94.4%) 315 (93.8%) n.s.
Nitroglycerin (yes, %) 131 (67.2%) 272 (81.0%) <0.001
Carperitide (yes, %) 131 (67.2%) 208 (61.9%) n.s.
Dopamine (yes, %) 44 (22.6%) 62 (18.5%) n.s.
Dobutamine (yes, %) 46 (23.6%) 55 (16.4%) 0.014
ACE-I/ARB (yes, %) 79 (40.5%) 142 (42.3%) n.s.
-Blocker (yes, %) 55 (28.2%) 100 (29.8%) n.s.
Spironolactone (yes, %) 78 (40.0%) 145 (43.2%) n.s.
NPPV, non-invasive positive pressure ventilation; ACE-I, angiotensin-converting
enzyme inhibitor; ARB, angiotensin II receptor blocker. p-Values are for between-
group comparisons.
Table 5
Multivariate logistic regression model for indicating nighttime heart failure.
Information OR 95%CI p-Value
SBP ≥164 mmHg 2.043 1.383–3.019 <0.001
HR  ≥114 beats/min 1.490 1.001–2.218 0.050
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wOrthopnea 2.257 1.377–3.701 0.002
R, odds ratio; CI, conﬁdence interval; SBP, systolic blood pressure; HR, heart rate.
The relationships between the treatment, including respiratory
upport and medications prescribed during the ﬁrst 5 days, and
he time of admission are shown in Table 4. The frequency of
on-invasive positive pressure ventilation (NPPV) and the rate of
ndotracheal intubation were not signiﬁcantly different between
he two groups. Nitroglycerin was used more frequently in group
 (81.0%) than in group D (67.2%), while on the other hand, dobut-
mine was used less frequently in group N (18.5%) than in group
 (22.6%). There were no signiﬁcant differences in the other med-
cations prescribed in the ﬁrst 5 days after admission between the
wo groups.
Finally, the results of the multivariate logistic regression model
or nighttime HF found that the speciﬁc factors differentiating
hese patients were a high SBP (≥164 mmHg) [p < 0.001, odds ratio
OR): 2.043; 95% conﬁdence interval (CI): 1.383–3.019], a high
R (≥114 beats/min) (p = 0.050, OR: 1.490; 95%CI: 1.001–2.218)
nd the presence of orthopnea (p = 0.002, OR: 2.257; 95%CI:
.377–3.701) (Table 5).
.3. Time of admission and outcomes
The results of a comparison of the outcomes in each group are
hown in Table 6. The length of ICU hospitalization was  signiﬁcantly
horter in group N (5.8 ± 10.5 days) than in group D (7.8 ± 11.5
ays). On the other hand, the length of total hospitalization and
n-hospital mortality were not signiﬁcantly different between the
wo groups.
able 6
omparison of the outcomes between the groups.
Daytime group
(n = 195)
Nighttime
group (n = 336)
p-Value
ICU stay (days) 7.8 ± 11.5 5.8 ± 10.5 0.018
Hospitalization (days) 35.7 ± 28.3 33.2 ± 31.9 n.s.
In-hospital mortality (yes, %) 16 (8.2%) 18 (5.4%) n.s.
CU, intensive care unit; p-value for between-group comparisons. The factors that
ere not normally distributed were compared by the Mann–Whitney U test.rdiology 61 (2013) 210–215 213
4. Discussion
A relationship between the clinical ﬁndings and time of admis-
sion in some patients with HF has been reported in previous
studies. Patients admitted in the daytime were more likely to
have systemic congestion, which developed gradually over days
or weeks. They were therefore more likely to wait until day-
time to present to the outpatient clinic [7]. On the other hand,
patients admitted in the nighttime were more likely to have high
blood pressure (hypertensive HF) and pulmonary edema. Kitzis
et al. demonstrated that patients with pulmonary edema are fre-
quently admitted in the late evening (between 20:00 and 24:00)
[8], and Pasqualetti et al. also demonstrated that the majority of
patients with pulmonary edema were admitted at night (between
22:00 and 04:00) [9]. These patients usually cannot wait until
morning for treatment, and therefore present to the emergency
department.
The present study demonstrated that AHF patients who  need
intensive care were admitted more frequently at night than dur-
ing the day. The independent factors associated with nighttime
admission for HF were a high SBP, high HR, and orthopnea.
Furthermore, the pH value was lower, and the frequency of pul-
monary congestion was  higher in the HF patients admitted at
night than in those admitted during the daytime. The administra-
tion of nitroglycerin was  more frequent, and the administration
of dobutamine was  less frequent in the HF patients admitted at
night than in those admitted during the day. The length of ICU
stay was shorter in the nighttime HF group than in the daytime HF
group.
4.1. Time of admission of AHF patients
There have been few reports that have evaluated the time of
admission in patients with AHF. Minami et al. reported the data
from the ATTEND registry [7],  and showed that AHF admission
is more common during the daytime, which was contrary to our
present ﬁndings. Our data showed that the patients with AHF
tended to be admitted to the ICU more frequently in the nighttime
than in the daytime.
The ATTEND registry included patients who had been admitted
to the general ward during the day, while on the other hand, all AHF
patients were admitted to the ICU in our present study. Our study
population included all New York Heart Association (NYHA) III or IV
patients, meanwhile, the patients in the ATTEND registry included
NYHA I or II patients (12.8%) [10]. Furthermore, the patients in the
present study were more likely to have orthopnea (83.4%) than
those in the ATTEND registry (65.6%), and they were also more likely
to include patients with LVEF ≤40% (62.9%) than in the ATTEND reg-
istry (53.8%). The serum levels of BNP were more highly elevated in
the patients described in the present study than in those reported
in the ATTEND registry [7]. The frequency of NPPV and the rate
of endotracheal intubation were all higher in the patients in the
present study (46.7% and 26.0%, respectively) than in those in the
ATTEND registry (36.1% and 11.1%, respectively), and dopamine and
dobutamine were also used more frequently in our present study
(20.0% and 19.0%, respectively) than in the ATTEND registry (12.7%
and 11.0%, respectively) [10]. These differences in the background
characteristics might indicate that there were more “acute” and
“severe” HF patients in the present population than in the ATTEND
registry. These differences in the study population might have led
to the difference in the time of admission between the two reports.
There are several possible reasons why  admission for AHF is
more frequent at night than during the day. One is the ﬂuid shift
that occurs at night. As orthopnea and paroxysmal nocturnal dys-
pnea are characteristic symptoms of HF [5,11],  the supine position
adopted during sleep increases venous return, which leads to an
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ncrease in the cardiac pre-load. Thus, this ﬂuid shift may  induce
HF more frequently at night.
.2. Vital signs, physical examination and the time of admission
The multivariate logistic regression model revealed that a high
BP and high HR on admission are the most important factors asso-
iated with nighttime HF.
The CS algorithm was originally advocated by Mebazaa et al.
n 2008 [6].  They classiﬁed AHF patients into 5 groups accord-
ng to their SBP, and demonstrated the clinical characteristics
nd primary treatment strategies for each group. CS 1 is deﬁned
or patients with a SBP >140 mmHg  and dyspnea related to dif-
use pulmonary edema but minimal systemic edema, and often
hows rapid worsening. CS 2 is deﬁned by a SBP of between
00 and 140 mmHg  with dyspnea and/or congestion, generally
eveloping gradually, along with a progressive increase in body
eight and systemic edema. CS 3 is deﬁned by a SBP of less than
00 mmHg, and is often associated with peripheral hypoperfusion.
n another previous report, CS 1 was explained as “vascular fail-
re” or “hypertensive HF”, CS 2 as “cardiac failure” or “peripheral
dema/congestion,” and CS 3 as “cardiogenic shock” or “low output
yndrome” [1,2,12].
We  demonstrated that CS 1 (vascular failure, hypertensive
F) was noted more often in the nighttime, and CS 2 (cardiac
ailure, peripheral edema/congestion) was more common in the
aytime. CS 1 (vascular HF, hypertensive HF) patients show acute
nset and rapid worsening of symptoms, which leads to a sharp
ncrease in endogenous catecholamine. As a result, the SBP and HR
re increased. Moreover, the rapid elevation of endogenous cate-
holamine might constrict peripheral vessels and lead to a low BT.
hese were all noted in the nighttime patients more often than in
he daytime patients.
.3. Arterial blood gas, laboratory data, chest X-rays, and the
ime of admission
Advanced acidosis, increased WBC  counts, and increased serum
lucose levels were characteristic of the nighttime HF patients with
egard to the laboratory data. Both metabolic and respiratory acid-
sis developed in the patients with AHF, because they opposed
he peripheral hypoperfusion and diminished diffusing capacity of
he lungs caused by pulmonary congestion or obstructive defects
aused by edematous bronchi [13]. There might be an insufﬁcient
mount of time to compensate the acid-base balance in patients
resenting with vascular failure because of its acute onset, there-
ore, the vascular failure (occurring more often in the nighttime) is
hus considered to show more advanced acidosis. Shirakabe et al.
emonstrated that the AHF patients with acidosis tended to show
 higher SBP, which is a characteristic of vascular failure, and they
lso more frequently demonstrated CS 1 [14]. The WBC  counts
ncreased upon the exacerbation of HF caused by inﬂammatory
rocesses [15,16]. The serum glucose levels were also increased,
ecause endogenous catecholamine and cortisol are secreted upon
he exacerbation of HF [17]. The nighttime HF patients showed
 particularly rapid worsening; therefore, these laboratory data
ight reﬂect a more rapid worsening HF.
The patients with pulmonary congestion on chest X-rays were
igniﬁcantly more common in the nighttime HF group. Pulmonary
ongestion rapidly develops as a ﬁrst response to acute left-side
F, especially at night. The volume shift at night and the circa-
ian variability of blood pressure may  play an important role in the
evelopment of pulmonary edema [8,18,19]. On the other hand,
leural effusion was more frequently observed in the daytime HF
han in the nighttime HF. Pleural effusion often appears as a result
f right-side HF or biventricular HF which accompanies systemicrdiology 61 (2013) 210–215
edema [20]. Right-side HF or biventricular HF gradually develops
in comparison to left-side HF. Therefore, the patients that were
characterized as having “cardiac HF” which was associated with
systemic edema tended to present more frequently with daytime
HF.
4.4. Treatment strategy and the time of admission
Nitroglycerin was  administered more frequently and dobut-
amine was administered less frequently in the nighttime HF
patients than in the daytime HF patients. Vascular HF/hypertensive
HF can be treated with vasodilators like nitroglycerin, and cardiac
failure/low output syndrome is generally treated with inotropic
agents like dobutamine, as explained in the ESC guideline [1].  CS
1, which was considered to be vascular HF/hypertensive HF, was
diagnosed signiﬁcantly more often in the nighttime HF patients
in the present study, while CS 2, which was  attributed to cardiac
failure, was less common in the nighttime HF patients. This could
explain the differences in the treatment strategy resulting from the
different times of admission. NPPV use tended to be more frequent
in the nighttime than in the daytime HF patients. The nighttime HF
patients often presented with rapidly developed pulmonary con-
gestion, so the use of NPPV would be reasonable to eliminate the
pulmonary edema by reducing the venous return [21–23].
4.5. Prognosis and the time of admission
The SBP on admission was  the most important factor predict-
ing the morbidity and mortality of AHF patients in recent reports
[24–28]. A report from the ATTEND registry demonstrated a poor
prognosis for daytime cardiac failure, and a good prognosis for
nighttime vascular failure [7].  The present study demonstrated that
the duration of ICU stay was  signiﬁcantly shorter in the nighttime
HF patients than in the daytime HF patients. This result might
indicate that the nighttime HF (vascular HF/hypertensive HF) is
associated with a better short-term prognosis than the daytime HF
(cardiac failure).
On the other hand, we did not ﬁnd any signiﬁcant differences
in the total duration of hospitalization or the in-hospital mortality
between the two groups. This may  be because the population of the
present study was limited to patients admitted to the ICU.
4.6. Study limitations
There are several limitations to the present study that should
be considered when interpreting the results. First, the population
evaluated in our study was  limited to only the patients admitted to
the ICU and AHF patients who were admitted to general wards were
excluded from this study. In other words, patients with severe AHF
who need intensive care might be admitted more frequently in the
nighttime than in the daytime. Second, the decision to admit to the
ICU was  determined by each physician, therefore, the admission
criteria to ICU were unclear. Third, this study was retrospective,
therefore, some patients were excluded because there were miss-
ing data. Fourth, the present study was  a single center study, with a
small number of patients included in each group. Therefore, there
might be a patient bias. For example, the SBP was relatively high in
this study population in comparison to other HF registries [28,29],
the rate of new-onset HF was high at 65.0%, and the etiology of HF
was mixed.
5. ConclusionIn conclusion, the patients with AHF who need to be treated in
the ICU were admitted more frequently at night than during the
day. The independent clinical ﬁndings associated with nighttime
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HF were a high SBP, high HR, and orthopnea, and the adminis-
ration of nitroglycerin was more frequent, and the administration
f dobutamine was less frequent in the nighttime HF patients. As a
esult, the length of ICU stay was shorter in the nighttime HF group.
This study provides new insights into the relationship between
he time of admission and the clinical ﬁndings for AHF, and sug-
ests that adding the concept of the “time of admission” should be
onsidered for the management of AHF.
isclosures
None declared.
cknowledgments
We  are grateful to the staff of the ICU and the medical records
fﬁce at Chiba Hokusoh Hospital, Nippon Medical School, for their
aluable assistance in collecting the medical data.
eferences
[1] Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-
Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW,  Keren A, Mebazaa
A,  Nieminen M,  Priori SG, Swedberg K, et al. ESC Guidelines for the diagnosis
and treatment of acute and chronic heart failure 2008: the Task Force for the
Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the Euro-
pean Society of Cardiology. Developed in collaboration with the Heart Failure
Association of the ESC (HFA) and endorsed by the European Society of Intensive
Care Medicine (ESICM). Eur Heart J 2008;29:2388–442.
[2]  Nieminen MS,  Harjola VP. Deﬁnition and epidemiology of acute heart failure
syndromes. Am J Cardiol 2005;96:5G–10G.
[3] Nieminen MS,  Bohm M,  Cowie MR,  Drexler H, Filippatos GS, Jondeau G, Hasin Y,
Lopez-Sendon J, Mebazaa A, Metra M,  Rhodes A, Swedberg K, Priori SG, Garcia
MA,  Blanc JJ, et al. Executive summary of the guidelines on the diagnosis and
treatment of acute heart failure: the Task Force on Acute Heart Failure of the
European Society of Cardiology. Eur Heart J 2005;26:384–416.
[4] Gheorghiade M,  Zannad F, Sopko G, Klein L, Pin˜a IL, Konstam MA,  Massie
BM, Roland E, Targum S, Collins SP, Filippatos G, Tavazzi L. Acute heart fail-
ure syndromes: current state and framework for future research. Circulation
2005;112:3958–68.
[5] McKee PA, Castelli WP,  McNamara PM,  Kannel WB.  The natural history of con-
gestive heart failure: the Framingham study. N Engl J Med  1971;285:1441–6.
[6] Mebazaa A, Gheorghiade M,  Pina IL, Harjola VP, Hollenberg SM,  Follath F,
Rhodes A, Plaisance P, Roland E, Nieminen M,  Komajda M, Parkhomenko A,
Masip J, Zannad F, Filippatos G. Practical recommendations for prehospital and
early in-hospital management of patients presenting with acute heart failure
syndromes. Crit Care Med  2008;36:S129–39.
[7] Minami Y, Kajimoto K, Sato N, Yumino D, Mizuno M,  Aokage T, Murai K,
Munakata R, Asai K, Sakata Y, Keida T, Hagiwara N, Mizuno K, Kasanuki H,
Takano T. Admission time, variability in clinical characteristics, and in-hospital
outcomes in acute heart failure syndromes: ﬁndings from the ATTEND registry.
Int J Cardiol 2011;153:102–5.
[8] Kitzis I, Zeltser D, Kassirer M,  Itzcowich I, Weissman Y, Laniado S, Keren
G,  Viskin S. Circadian rhythm of acute pulmonary edema. Am J Cardiol
1999;83:448–50. A9.
[9] Pasqualetti P, Casale R. Daily distribution of episodes of acute cardiogenic pul-
monary edema. Cardiology 1997;88:509–12.10] Sato N, Kajimoto K, Asai K, Mizuno M,  Minami Y, Nagashima M,  Murai K,
Muanakata R, Yumino D, Meguro T, Kawana M,  Nejima J, Satoh T, Mizuno K,
Tanaka K, et al. Acute decompensated heart failure syndromes (ATTEND) reg-
istry. A prospective observational multicenter cohort study: rationale, design,
and preliminary data. Am Heart J 2010;159:949–55.e1.
[rdiology 61 (2013) 210–215 215
11] Ekundayo OJ, Howard VJ, Safford MM,  McClure LA, Arnett D, Allman RM,
Howard G, Ahmed A. Value of orthopnea, paroxysmal nocturnal dyspnea, and
medications in prospective population studies of incident heart failure. Am J
Cardiol 2009;104:259–64.
12] Gheorghiade M,  De Luca L, Fonarow GC, Filippatos G, Metra M,  Francis GS.
Pathophysiologic targets in the early phase of acute heart failure syndromes.
Am J Cardiol 2005;96:7G–11G.
13] Snashall PD, Chung KF. Airway obstruction and bronchial hyperrespon-
siveness in left ventricular failure and mitral stenosis. Am Rev Respir Dis
1991;144:945–56.
14] Shirakabe A, Hata N, Kobayashi N, Shinada T, Tomita K, Tsurumi M, Matsushita
M,  Okazaki H, Yamamoto Y, Yokoyama S, Asai K, Mizuno K. Clinical signiﬁ-
cance of acid–base balance in an emergency setting in patients with acute heart
failure. J Cardiol 2012;60:288–94.
15] Pﬁster R, Sharp SJ, Luben R, Wareham NJ, Khaw KT. Differential white blood cell
count and incident heart failure in men and women in the EPIC-Norfolk study.
Eur Heart J 2011;33:523–30.
16] Engstrom G, Melander O, Hedblad B. Leukocyte count and incidence of hospi-
talizations due to heart failure. Circ Heart Fail 2009;2:217–22.
17] Oswald GA, Smith CC, Betteridge DJ, Yudkin JS. Determinants and importance
of  stress hyperglycaemia in non-diabetic patients with myocardial infarction.
Br Med  J (Clin Res Ed) 1986;293:917–22.
18] O’Brien E, Sheridan J, O’Malley K. Dippers and non-dippers. Lancet 1988;2:
397.
19] Boggia J, Li Y, Thijs L, Hansen TW,  Kikuya M,  Björklund-Bodegård K, Richart
T,  Ohkubo T, Kuznetsova T, Torp-Pedersen C, Lind L, Ibsen H, Imai Y, Wang
J,  Sandoya E, et al. Prognostic accuracy of day versus night ambulatory blood
pressure: a cohort study. Lancet 2007;370:1219–29.
20] Natanzon A, Kronzon I. Pericardial and pleural effusions in congestive heart
failure-anatomical, pathophysiologic, and clinical considerations. Am J Med Sci
2009;338:211–6.
21] Rasanen J, Heikkila J, Downs J, Nikki P, Vaisanen I, Viitanen A. Continuous posi-
tive airway pressure by face mask in acute cardiogenic pulmonary edema. Am
J  Cardiol 1985;55:296–300.
22] Bersten AD, Holt AW,  Vedig AE, Skowronski GA, Baggoley CJ. Treatment of
severe cardiogenic pulmonary edema with continuous positive airway pres-
sure delivered by face mask. N Engl J Med  1991;325:1825–30.
23] Shirakabe A, Hata N, Yokoyama S, Shinada T, Kobayashi N, Tomita K, Kitamura
M,  Nozaki A, Tokuyama H, Asai K, Mizuno K. Predicting the success of noninva-
sive positive pressure ventilation in emergency room for patients with acute
heart failure. J Cardiol 2010;57:107–14.
24] Gheorghiade M,  Abraham WT,  Albert NM,  Greenberg BH, O’Connor CM, She
L, Stough WG,  Yancy CW,  Young JB, Fonarow GC. Systolic blood pressure at
admission, clinical characteristics, and outcomes in patients hospitalized with
acute heart failure. JAMA 2006;296:2217–26.
25] Zannad F, Mebazaa A, Juilliere Y, Cohen-Solal A, Guize L, Alla F, Rouge P, Blin P,
Barlet MH,  Paolozzi L, Vincent C, Desnos M, Samii K. Clinical proﬁle, contempo-
rary  management and one-year mortality in patients with severe acute heart
failure syndromes: the EFICA study. Eur J Heart Fail 2006;8:697–705.
26] Tavazzi L, Maggioni AP, Lucci D, Cacciatore G, Ansalone G, Oliva F, Porcu M.
Nationwide survey on acute heart failure in cardiology ward services in Italy.
Eur Heart J 2006;27:1207–15.
27] Abraham WT,  Fonarow GC, Albert NM,  Stough WG,  Gheorghiade M,
Greenberg BH, O’Connor CM,  Sun JL, Yancy CW,  Young JB. Predictors of
in-hospital mortality in patients hospitalized for heart failure: insights
from the Organized Program to Initiate Lifesaving Treatment in Hospital-
ized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol 2008;52:
347–56.
28] Adams Jr KF, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR,  Abra-
ham WT,  Berkowitz RL, Galvao M,  Horton DP. Characteristics and outcomes
of  patients hospitalized for heart failure in the United States: rationale, design,
and  preliminary observations from the ﬁrst 100,000 cases in the Acute Decom-
pensated Heart Failure National Registry (ADHERE). Am Heart J 2005;149:
209–16.
29] Fonarow GC, Abraham WT,  Albert NM,  Gattis WA,  Gheorghiade M,  Greenberg
B,  O’Connor CM,  Yancy CW,  Young J. Organized Program to Initiate Lifesaving
Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale
and design. Am Heart J 2004;148:43–51.
